Tumour Marker Blood Tests UK: What They Find, What They Don't (2026)

Tumour marker blood tests in the UK: what they find, what they don’t, and when they’re useful

Cancer blood tests sound like they should be the dream screen — one tube of blood, a clear answer. Reality is more complicated. The “tumour markers” available privately are useful in specific situations, often misleading in others, and almost never the right standalone test for screening healthy people.

Below is a plain-English guide to the main tumour markers available privately in the UK, what each one tells you, and when they’re worth ordering.

The short answer

Tumour markers are blood proteins (or other molecules) that some cancers release into the bloodstream. They’re most useful for:

• Monitoring known cancer during and after treatment

• Investigating specific symptoms alongside other tests

• Stratifying risk in some screening scenarios (e.g. PSA for prostate)

They’re rarely useful as standalone screening tests in healthy asymptomatic people because:

• They’re not specific to cancer (many benign conditions raise them)

• Many early cancers don’t raise them at all

• A normal result doesn’t rule out cancer

• A raised result usually doesn’t mean cancer

A blood panel marketed as “cancer screening” using tumour markers should be approached with informed caution.

The main tumour markers available privately

PSA — Prostate Specific Antigen

Cancer relevance: prostate cancer Cost: £40–£90 Useful for: men over 50, or 45+ with risk factors, as part of prostate screening Limits: raised by benign prostate enlargement, infection, recent sex or cycling; misses about 15% of prostate cancers Verdict: the most useful single tumour marker for screening, but needs clinical interpretation

For full detail on prostate screening, see our private prostate cancer screening guide.

CA125 — Cancer Antigen 125

Cancer relevance: ovarian cancer (mainly) Cost: £50–£90 Useful for: investigating symptoms suspicious for ovarian cancer (bloating, pelvic pain, urinary changes), monitoring known ovarian cancer Limits: raised by endometriosis, fibroids, pregnancy, menstruation, pelvic infection, liver disease; misses many early ovarian cancers; can be raised in other cancers Verdict: useful for investigating symptoms, not useful for general screening

CEA — Carcinoembryonic Antigen

Cancer relevance: bowel cancer, sometimes lung, breast, pancreatic Cost: £40–£70 Useful for: monitoring known bowel cancer after treatment to detect recurrence Limits: raised by smoking, liver disease, IBD, infections; not sensitive enough for screening; misses early bowel cancer Verdict: useful for surveillance, not useful for screening. For bowel cancer screening, ColoAlert and colonoscopy are far better. See our ColoAlert vs FIT test guide.

AFP — Alpha-Fetoprotein

Cancer relevance: liver cancer (hepatocellular carcinoma), some testicular cancers, some ovarian Cost: £40–£70 Useful for: liver cancer surveillance in people with cirrhosis or chronic hepatitis, monitoring testicular cancer Limits: also raised in pregnancy, liver disease, hepatitis; misses many early liver cancers Verdict: useful in specific surveillance contexts, not useful for general screening

CA19-9 — Cancer Antigen 19-9

Cancer relevance: pancreatic cancer (mainly), bile duct, stomach Cost: £50–£90 Useful for: monitoring known pancreatic cancer Limits: raised by pancreatitis, gallstones, jaundice from any cause; not sensitive enough for screening; about 10% of people genetically can’t produce it at all Verdict: monitoring only, not screening

CA15-3 — Cancer Antigen 15-3

Cancer relevance: breast cancer Cost: £50–£90 Useful for: monitoring known metastatic breast cancer Limits: poor sensitivity for early breast cancer; raised in many benign conditions Verdict: never useful for screening; limited even in monitoring early disease

HCG — Human Chorionic Gonadotropin

Cancer relevance: germ cell tumours (testicular, some ovarian), choriocarcinoma Cost: £30–£60 Useful for: suspected testicular cancer alongside imaging, pregnancy testing Limits: also produced in pregnancy; not useful for routine cancer screening Verdict: specific clinical use only

Calcitonin

Cancer relevance: medullary thyroid cancer (rare) Cost: £60–£100 Useful for: investigation of suspicious thyroid nodules, family history of medullary thyroid cancer or MEN2 syndrome Limits: highly specific to a rare cancer Verdict: very niche

Chromogranin A

Cancer relevance: neuroendocrine tumours Cost: £80–£130 Useful for: investigation of suspected neuroendocrine tumours (carcinoid syndrome) Limits: raised by acid-suppressing medications (PPIs), kidney impairment, heart failure Verdict: specific clinical use only

Galleri test (multi-cancer early detection)

Cancer relevance: screen for many cancers simultaneously by detecting cancer DNA in blood Cost: £700–£1,000 Useful for: comprehensive screening, particularly in older adults at higher cancer risk Limits: newer technology, real-world performance still being studied, false-positive and false-negative rates published but evolving, doesn’t replace existing screens like FIT, mammography, PSA Verdict: promising but should complement, not replace, established screening. NHS England has been trialling it but it’s not yet recommended for routine population screening.

Why “cancer screening blood panels” can be misleading

Several private services market panels that combine 4–8 tumour markers as a “comprehensive cancer screen” for £200–£500.

The clinical reality:

• Most early cancers don’t raise these markers — so a normal panel is falsely reassuring

• Many benign conditions raise them — so a raised result usually triggers anxiety and investigation that turns out to be unnecessary

• The combination isn’t more sensitive than the sum of its parts — adding more imperfect tests doesn’t fix the underlying problem

• They miss the cancers that proper screening would catch (lung CT, mammography, FIT or ColoAlert, prostate MRI, cervical screening)

A “tumour marker panel” sounds like cancer screening but isn’t really. The exception is PSA, which is genuinely a useful screening test (with its known limits).

When tumour markers are genuinely useful

Tumour markers earn their place in three situations:

1. Investigating a specific symptom

If you have bloating, abdominal pain and abnormal periods, CA125 alongside ultrasound is reasonable. If you have unexplained weight loss and jaundice, CA19-9 alongside imaging is reasonable. The key is that the test is targeted to the clinical question, not a fishing expedition.

2. Monitoring known cancer

After surgery for bowel cancer, serial CEA tests can detect recurrence before imaging. After surgery for ovarian cancer, CA125 monitoring is standard. This is where these tests actually save lives — but the patient already has a cancer diagnosis.

3. Specific high-risk screening

PSA in men over 50, AFP in cirrhosis patients, calcitonin in MEN2 families — these have clear evidence of benefit in defined high-risk groups.

What to do instead for general cancer screening

A clinically rigorous approach to cancer screening for an average-risk adult looks more like:

For everyone: - NHS bowel cancer screening (FIT every 2 years from 50, lowering) - Or private ColoAlert if you want better accuracy

For women: - NHS cervical screening (every 3 years 25–49, every 5 years 50–64) - NHS or private mammography from age 40–50 onwards (see our breast cancer screening guide)

For men: - PSA testing from age 50 (or 45 if higher risk) - Plus MRI if PSA raised — see our prostate cancer screening guide

Smokers and ex-smokers: - Low-dose CT lung screening from age 55–80 if eligible

Anyone with significant family cancer history: - Genetic counselling and risk-based surveillance

Skin: - Annual visual examination (not a blood test)

This is what cancer screening actually looks like in 2026. A tumour marker panel is at best a supplementary tool, not a replacement.

What a proper cancer-focused private health screen looks like

If you want a comprehensive private cancer screen, a reasonable package might include:

• Detailed personal and family history review with a GP

• ColoAlert for bowel cancer

• Mammogram and ultrasound for women 40+

• PSA + clinical exam for men 50+

• Pelvic ultrasound for women (if indicated)

• Skin examination

• Low-dose CT chest if smoking history

• Targeted blood tests (full blood count, kidney/liver function, vitamin D, thyroid)

• Tumour markers only where clinically indicated

• Follow-up MRI or other imaging if findings warrant it

Total cost: £600–£1,500 depending on tests included. More clinical value than a generic “tumour marker panel” at any price.

Frequently asked questions

Should I have a tumour marker panel “just to check”? Generally no. The chance of a true cancer found that wouldn’t be picked up by symptom history, examination, and standard screens is small. The chance of a false-positive that triggers unnecessary investigation is much higher.

My friend’s tumour marker was raised — should I panic? No. Most raised tumour markers in asymptomatic people are not cancer. They need clinical interpretation, often a repeat test, and possibly some targeted imaging. Most resolve without finding cancer.

What if I just want reassurance? Be honest about that with your GP. Sometimes a well-designed screening package provides genuine reassurance. Sometimes the right intervention is dealing with the underlying anxiety, not piling on tests that may make it worse.

Are home cancer screening kits any good? Mixed. ColoAlert (stool DNA test) and FIT (stool blood test) are validated and useful. Most “at-home” tumour marker panels are essentially blood draws with the same limitations as clinic-based ones, often without proper interpretation.

Will my health insurance cover tumour marker tests? Usually only when there’s a specific clinical indication, not for screening. Check before booking.

What about the Galleri test specifically? It’s the most interesting development in this space. Multi-cancer early detection by analysing cancer DNA in blood. Promising real-world performance, but it’s a complement to existing screening, not a replacement. Still under evaluation in the UK.

In summary

Tumour markers are useful tools in the right hands and the wrong test for almost any healthy adult who wants to “screen for cancer.” A normal result doesn’t reassure; a raised result usually isn’t cancer.

If you want to take cancer screening seriously, do the screens that work — bowel screening, cervical screening, mammography, PSA where appropriate, lung CT for smokers — and have a clinician build a plan around your risk profile.

A blood test alone won’t catch most cancers. A well-designed pathway, including the right blood tests, often will.

About the author

Dr Chun Tang (MBChB, MRCGP, MBA) is a GMC-registered private GP and co-founder of Northwest Health in Bamber Bridge, Preston. He is Medical Director of Biox Medical Ltd (UK distributor of ColoAlert®) and has been featured in The Daily Telegraph, The Mirror, BBC and GB News.

Want a properly thought-through cancer screening plan?Book a private GP consultation to discuss the right tests for your age, family history and risk factors.